These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 19570025)

  • 1. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.
    Greggio E; Cookson MR
    ASN Neuro; 2009 Apr; 1(1):. PubMed ID: 19570025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.
    Xiong Y; Dawson VL; Dawson TM
    Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
    Greggio E
    Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites.
    Greggio E; Taymans JM; Zhen EY; Ryder J; Vancraenenbroeck R; Beilina A; Sun P; Deng J; Jaffe H; Baekelandt V; Merchant K; Cookson MR
    Biochem Biophys Res Commun; 2009 Nov; 389(3):449-54. PubMed ID: 19733152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.
    West AB; Moore DJ; Choi C; Andrabi SA; Li X; Dikeman D; Biskup S; Zhang Z; Lim KL; Dawson VL; Dawson TM
    Hum Mol Genet; 2007 Jan; 16(2):223-32. PubMed ID: 17200152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.
    Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ
    PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 in Parkinson's disease: protein domains and functional insights.
    Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
    Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
    Seol W
    BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The biology and pathobiology of LRRK2: implications for Parkinson's disease.
    Moore DJ
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S92-8. PubMed ID: 18602856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of GTPase activity to LRRK2-associated Parkinson disease.
    Tsika E; Moore DJ
    Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
    Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
    ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
    Gandhi PN; Chen SG; Wilson-Delfosse AL
    J Neurosci Res; 2009 May; 87(6):1283-95. PubMed ID: 19025767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.
    Cookson MR
    Nat Rev Neurosci; 2010 Dec; 11(12):791-7. PubMed ID: 21088684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring the activity of leucine-rich repeat kinase 2: a kinase involved in Parkinson's disease.
    Lee BD; Li X; Dawson TM; Dawson VL
    Methods Mol Biol; 2012; 795():45-54. PubMed ID: 21960214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.
    Rudenko IN; Cookson MR
    Neurotherapeutics; 2014 Oct; 11(4):738-50. PubMed ID: 24957201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.
    Biosa A; Trancikova A; Civiero L; Glauser L; Bubacco L; Greggio E; Moore DJ
    Hum Mol Genet; 2013 Mar; 22(6):1140-56. PubMed ID: 23241358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease.
    Gómez-Suaga P; Fdez E; Fernández B; Martínez-Salvador M; Blanca Ramírez M; Madero-Pérez J; Rivero-Ríos P; Fuentes JM; Hilfiker S
    Neuropharmacology; 2014 Oct; 85():45-56. PubMed ID: 24863040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.
    Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR
    Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 pathobiology in Parkinson's disease.
    Martin I; Kim JW; Dawson VL; Dawson TM
    J Neurochem; 2014 Dec; 131(5):554-65. PubMed ID: 25251388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.